

**ADDRESS**

Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN.

Email: : [l.lightstone@imperial.ac.uk](mailto:l.lightstone@imperial.ac.uk).

Mobile phone : on request PA, Anjali Jagpal : +44 (0)208 383 3152

**CURRENT POSITIONS****Employment:**

Aug 2014 - date Professor of Renal Medicine (promoted from Reader August 2014) – Imperial College London (0.9 WTE since Jan 2014, 0.8 WTE 2002-14, 1.0 WTE 1995-2002)

Oct 1995 - date Honorary Consultant Physician – Renal and Transplant Centre, Imperial College NHS Healthcare Trust (ICHNT), Hammersmith Hospital

Sept 2019-2023 Consul (Clinical) Faculty of Medicine, Imperial College London

Sept 2018- date Deputy Campus Director, Imperial College London Hammersmith and White City Campus

**Membership of important committees or advisory groups:**

2022- Chair, Data Monitoring Committee, Novartis Lupus Nephritis trial cVAY736K12301 LN

2021-2023 ISN President's selection to sit on the ISN Executive Committee

2021-2023 International Soc Nephrology (ISN) : Elected Deputy Chair of the Western Europe Regional Board; Member of Council of the ISN;

2021- Invited member, OMERACT 2022 SLE Working Group to update core outcomes in SLE

2021 Co-Chair International Advisory Panel, GSK Global GUIDE program – Virtual Scientific Forum

2021 Member, International Working Group on Glomerular Diseases and Pregnancy – co lead for lupus nephritis and oversight of whole document

2021- Member, Bristol Myers Squibb Rheumatology / Renal Lupus Nephritis Advisory Council

2020-2021 Renal Association Clinical Expert, new NICE STA of belimumab for the treatment of lupus; NICE STA of anifrolumab for the treatment of SLE; NICE STA of belimumab for the treatment of lupus nephritis

2020 Data Monitoring Committee Member, TACTIC-R trial (NCT04390464)

2020-2022 Member (from March) and Co-Chair (from Dec) COVID-19 Treatment and guideline group, ICHNT

2020 Co-Chair, COVID-19 Rapid Synthesis Best Evidence Group, ICHNT

2020 Chair, Renal Association COVID-19 working group for advice on shielding and unshielding of non-transplant immunosuppressed renal patients

2020 American Society of Nephrology Kidney Week - Abstract Category Chair for Women's Health and Kidney Diseases

2019- Advisory Board Member, Nature Reviews Nephrology

2019-2022 Elected member, Women in Nephrology Executive Committee (only non US member)- particular focus on international involvement and engagement

2019-2023 Member, Imperial College London Academic Promotions Committee

2018 Dec -2022 Trustee, Kidney Research UK

2018 – date Co-Chair (with Prof Dan Cattran, Toronto) of the SONG-GD (Glomerular Disease) Steering Group

2017 - 2022 Member, Can-SOLVE CKD (\$40million programme) International Research Advisory Committee (CIRAC)

2015 – 2022 Co-Chair, UK Kidney Research Consortium (UKKRC) Glomerulonephritis Clinical Study Group

2013 – date National Coordinator, RaDaR Pregnancy and Chronic Kidney Disease Rare Disease Group, Jan 2013 to Dec 2014, continue as committee member Dec 14 onwards

2012 – date Member, EU Executive of the Global Lupus Nephritis Trial Network

**Previous posts:**

2012- 2020 Academic Lead for Renal Training, NW London Renal Training Programme

2010 – 2020 Renal Lead, Imperial College Faculty of Medicine Postgraduate Clinical Academic Training Committee

2018 Renal Association lead ISN World Kidney Day; organized national conference on Pregnancy & Kidney Disease at RCP London; arranged open access for key articles on women's health & kidney disease

2017 – 2019 Member, Renal Association Guideline on Pregnancy and Renal Disease working group

2016 - 2019 Member, MRC MASTERPLANS consortium PLANS management group

2016 - 2019 Medical Advisor to LUPUS UK

2016 – 2018 Co-opted Renal Expert; NICE Guideline on the Intrapartum Care of the High Risk Pregnancy ([www.nice.org.uk/guidance/ng121](http://www.nice.org.uk/guidance/ng121))

2016 - 2018 Council member, Royal Society of Medicine Nephrology Section

2014 - 2016 Rare Renal Org: Member, Operational Management Board and Rare Disease Committee

2013 – 2016 Member, Grants Committee, LUPUS UK

2010-2012 Associate Dean and Interim Director, North West Thames Foundation School

2010-2015 Member: Faculty of Medicine(FoM) Education Strategic Advisory Panel (2010), FoM Strategic Education Committee (2010-15), Graduate Entry Committee (til 2012).

2010-2014 UK Kidney Week – member programme planning committee

2010-2015 Member, Lupus UK Peer Review Panel

2009-2015	Director, North West Thames Foundation School Academic Foundation Programme since 2009 and Chair, (2010-15) Pan Thames Foundation Academic Leads Group and Foundation Academic Lead on London Deanery Academic Forum
2009-2015	Renal Association Clinical Expert, NICE STA of Belimumab for the treatment of lupus
2009-2012	Elected member of the Renal Association Executive Committee. Member of Clinical Affairs Board, Education and Training committee, and Equal Opportunities Group – remain active on the latter
2008-2014	West London Lead, UK Kidney Research Consortium and UK CRN National Speciality Group for Renal
2004-2012	Academic Lead on London Renal Speciality Training Committee – disbanded in 2012
1991-1995	MRC Clinician Scientist Training Fellow, Dept of Immunology, Royal Postgraduate Medical School (Supervisor: Professor Robert Lechler). Completed SpR training
1988-1991	MRC Clinical Training Fellow, ICRF Tumour Immunology Unit, UCL (Supervisor: Professor Av Mitchison)

## EDUCATION AND POSTGRADUATE QUALIFICATIONS

1996	FRCP	Royal College of Physicians
1995	GMC	Specialist Register in Renal and General Medicine; GMC number: 2838490
1993	PhD	University of London
1986	MRCP (UK)	Royal College of Physicians
1983	MBBS (Hons)	Proxime Accessit (runner up to the Gold Medallist), University of London
1983	Senior Scholar	Kings College Hospital Medical School
1980	BA (1st Class)	Medical Science Tripos, Cambridge University

## CURRENT RESEARCH FUNDING

2022-2024	Improving our understanding of auto-immunity following kidney transplantation: biomarkers, outcomes and the link with alloimmunity. Kidney Research UK Clinical Training award to Dr Sarah Gleeson £178,028.19
2021-2023	MELODY (Mass Evaluation of Lateral flow immunoassays to Detect SARS-COV-2 antibody responses in immunocompromised patients) study – 23/9 invited by MRC to submit fast track application by 30/9 – awarded 14/10 - £900k; together with Kidney Research UK, Blood Cancer UK, Lupus UK, Vasculitis UK & The Cystic Fibrosis Trust; extension awarded by UKRI-MRC in May 2022.
2019-2024	NIHR HTA research award – The use of Rituximab in the treatment of nephrotic glomerulonephritis (TURING Trial); <i>Co-PI</i> - £1,393,360.85 – (ISRCTN 16948923) Phase 3
2021-2023	Alexion - A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participant With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN); ALXN1210-NEPH-202; <i>National Coordinator</i> ; (NCT0456433)
2020-2025	Novartis - A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active LN; SELUNE; <i>National Coordinator</i> ; Phase 3 (NCT04181762)
2020-2024	Roche - A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY); <i>Local PI</i> (NCT04221477) Phase 3
2019-2024	Novartis – Study on safety and efficacy of LNP023 in C3 glomerulopathy patients transplanted and not transplanted (NCT03832114) and extension study of LNP023 in C3GN (NCT03955445); <i>Local PI</i> ; Phase 2
2015-2020	MRC Stratified Medicine Call. “Maximizing the Therapeutic Potential by Application of Novel and Stratified approaches” (MASTERPLANS) UK lupus consortium bid for £4.124 million. My key role is in Work Strand 3 (Tissue & circulating biomarkers of remission/LDA in patients with lupus nephritis) - £720,400 of the total grant.
2018-2021	PREgnancy-associated progression of chronic kidney Disease: development of a Clinical predictive Tool (PREDICT) Kidney Research UK £110,557.24; <i>Local PI</i>

## RESEARCH SUPERVISION

### PhD

2021-2024	Dr Sarah Gleeson “Improving our understanding of auto-immunity following kidney transplantation: biomarkers, outcomes and the link with alloimmunity” (started as MRes, upgraded to PhD, (Interruption of studies due to COVID-19 work); 10 papers and 2 reviews to date; 4 first author
2016-2021	Dr Hannah Wilson “Molecular profiling of the kidney biopsy in lupus nephritis to identify the predictors of response to treatment” (Mat leave Oct 2019- Dec 2020) 1 <sup>st</sup> author – Kidney Int 2019; joint 1 <sup>st</sup> author Kidney Int 2017; plus 2 reviews. 2 x 1 <sup>st</sup> author papers in prep
2014-2020	Dr Kate Wiles (Mat leave – Sept 2015-Sept 2016) “The implications of chronic kidney for pregnancy: disease definitions, and the diagnosis and prediction of adverse outcome” Awarded July 2020; 6 1 <sup>st</sup> author (1 joint) and 2 reviews.
2010-2014	Dr Kate Bramham (Maternity Leave x 2; Awarded 2015 Dec) – 12 joint publications with me – 4 1 <sup>st</sup> author, 3 senior author; plus 2 reviews/chapters
1997-2004	Dr Afzal Chaudhry “Cell mediated Immunity in the development of crescentic GN” 3 second author papers
1996-2001	Dr Alan Salama “Immune regulation in renal disease” 3 first author papers

## MD (Res)

- 2010-2014 Dr Marie Condon – “Improving outcomes in glomerulonephritis” (Mat Leave x 2, Awarded Sept 2015).4 papers, 1 1<sup>st</sup> author (401 citations)
- 2000-2004 Dr Majdah Barhamein “Monitoring outcomes in lupus nephritis”

## RECENT KEYNOTE AND INVITED TALKS

- 2022 Multiple virtual talks on Lupus nephritis / Pregnancy and CKD – e.g. British Columbia, University of Texas SW Lupus nephritis day, ISN endorsed GN meeting in Dubai, WiInCon (Women in India conference August 2022), Ceylon College of Physicians Annual Academic Sessions Sept 2022.
- 2022 **European Renal Association** – Chaired 2 sessions and gave talk on advanced CKD and pregnancy May 2021
- 2021 **Inaugural Women in Nephrology India Symposium** – CKD and pregnancy. August 2021
- 2021 **Peter Schur Visiting Professor**, Brigham and Women’s Rheumatology Grand Rounds April 2021
- 2021 **Lupus Academy (online)** – Case study interactive workshop – “Lupus Nephritis”
- 2020 **Lupus Academy (online)** – Case study interactive workshop – “Fertility and pregnancy issues in patients with lupus nephritis” (have presented at Lupus Academy various talks - 2013, 14, 16, 19)
- 2020 **ERA-EDTA 2020 (online) -Gold plenary** – Addressing the Challenges posed by pregnancy in CKD
- 2019 **Israel Society of Rheumatology** - invited speaker and round table discussant
- 2019 **EULAR Congress 2019** - Update on the treatment of lupus nephritis
- 2019 **UK Kidney Week 2019** – Chair, “Reproductive Health and the kidney”; Invited speaker: “Balancing risk – what to advise when it’s all going very badly”
- 2019 **Frontiers in Glomerulonephritis – Royal Society of Medicine: What’s new in lupus nephritis**
- 2018 **Hong Kong Society of Nephrology – Educational Symposium 2018** – Invited talks on “All a nephrologist should know about pregnancy” and “Lupus nephritis: concerns and management”
- 2018 **UK Kidney Week 2018 – Walking in the shoes of a professor – trainees session.**
- 2017 **All India Institute of Medical Sciences (AIIMS)** – Glomerulonephritis Conclave, Faculty (one of 4)
- 2017 **Kidney Research UK Fellows Day** – Keynote Speaker: “Phenotyping – the long and winding road from bench to bedside and back again”
- 2017 **Controversies in Rheumatology & Autoimmunity** – Chair and debated “Steroids can be minimized in LN”
- 2017 **Irish Society of Nephrology** - Managing lupus nephritis in the 21<sup>st</sup> century
- American Society Nephrology Kidney Week:**
- 2022 Invited talks on Pregnancy and Glomerular Disease and updates on lupus nephritis; also chairing session
- 2021 Invited talks on Pregnancy and Glomerular Disease and updates on lupus nephritis; also chairing session
- 2020 Invited talk: Pregnancy and lupus nephritis
- 2019 Managing Glomerulonephritis During Pregnancy
- 2019 Moderator of “Lupus Nephritis in 4 Acts” session
- 2018 Invited talk: Minimizing Glucocorticoids in Lupus Nephritis: The Evidence
- 2016, 2017, 2020: Early program on Glomerular Disease: Pregnancy & Glomerular Disease
- American College Rheumatology annual meeting**
- 2020 Invited talk: Lupus nephritis: Updates in diagnosis and treatment- Calcineurin inhibitors and more
- 2019: TED Talk: Steroid Free Remission in Lupus Nephritis
- 2014-16: Meet the Professor – Novel approaches to treating lupus nephritis
- World Congress of Nephrology:**
- 2022
- 2021 Invited talk – Lupus nephritis and pregnancy; Co-Chair and organiser Women in Nephrology session at the WCN – “Challenging the Status Quo”
- 2020 Co-Chair session “Acute kidney disorders and pregnancy -From the common to the critical” and speaker :Lupus nephritis presenting in pregnancy (cancelled because of COVID-19 pandemic)
- 2019: Pregnancy in lupus and other auto-immune diseases
- Other invited talks**
- 2019: **ApEx-CS 2019 Board Review Course Mumbai** – 4 talks: 1. Vasculitis: what makes the diagnosis. 2. Are MAbs the holy grail for the treatment of LN ? 3. Withdrawing immunosuppression in Lupus. 4. Recent developments in the treatment of adult Nephrotic Syndrome.
- 2017: **Controversies in Rheumatology & Autoimmunity**; chair, & debated “Steroids can be minimized in LN”.
- 2016: **Chandos Lecture at UK Kidney Week** – “Pregnancy and Kidney Disease: the 3 Ps”
- 2016: **Society Obstetric Med Aus NZ annual meeting (SOMANZ)**, 2 plenary talks and panel discussion
- 2016: **Kolkata Lupus Initiative**, 2 plenary talks

## NATIONAL TEACHING TALKS many recurrent as excellent feedback) on lupus nephritis or pregnancy & kidney disease

- Since 2009: Annual UK Renal Association Advanced Nephrology Course; Renal disease and pregnancy
- Since 2009: Annual Imperial Renal Path course-co-organise, chair, speak; Lupus nephritis
- 2010 - 2019: Annual Imperial Immunology Update -Course organizer, speaker

## KEY CONTRIBUTIONS TO HEALTHCARE

### 1. Improving outcomes in glomerular diseases especially lupus nephritis (LN)

- a. Developed a joint renal / rheumatology clinic in lupus and now includes dermatology – provide a weekly clinic with

*joint care; a weekly MDT to review patients and I am widely consulted nationally and internationally for advice on complex patients – considered a world authority on best management of LN.*

- b. Developed the paradigm of steroid avoidance and steroid sparing in multiple GNs but most notably in LN*
  - i. the RITUXILUP and RITUXIRESCUE regimens for LN; now increasingly widely adopted
  - ii. The MinTac trial in minimal change disease (MCD): helped design the protocol of the largest adult study to demonstrate de novo MCD can be treated effectively with just tacrolimus and no steroids
  - iii. Advisor to numerous Pharma companies on recent trials in LN and have directly influenced the reduction in steroids that has consistently been adopted in all trial protocols since 2012 – with improved outcomes for patients
  - iv. Sole nephrologist on the global panel that developed the Glucocorticoid Toxicity Index that is now a standard index allowing comparison of steroid associated morbidity and steroid sparing treatment approaches in clinical trials across different diseases where different steroid doses are compared.
  - v. Demonstrated feasibility and safety of treating LN in pregnancy with tacrolimus and no oral steroid
- c. Improving patient engagement with treatment and outcomes*
  - i. Developed therapeutic drug monitoring for hydroxychloroquine which identifies non adherence and increased risk of LN flare. Improves patient engagement with self management.
  - ii. Initiated the SONG-GD (Standardised Outcomes in Nephrology-Glomerular Disease) initiative and co-chair the Global Steering committee. Have identified core outcomes important to patients, caregivers and health professionals including novel PROMs that now need to be developed into measurable scores and incorporated into future trials. Identified the importance of ‘life participation’ rather than mortality for patients. Multiple publications since 2019
  - iii. Via SONG, have contributed to qualitative work to improve terminology used for patients with kidney disease that is less confusing and frightening and will improve engagement with healthcare
  - iv. Via my roles with the ISN and Women in Nephrology am shaping the strategy for improving outcomes in kidney disease globally in general and promoting diversity in the workforce.
- d. Enhancing research and clinical trials in glomerular disease*
  - i. Have led and participated in multiple clinical trials in GD – investigator led and commercial. Developed and led the RITUXILUP trial (ms in prep), national CI on 3 LN trials currently, local PI on several more in LN, C3GN, IgA, minimal change and FSGS
  - ii. Co-Chair of the UKKRC GN Clinical Study Group – grew this group from a few participants to an actively engaged body of >150 stakeholders including patients, charity funders and clinicians. This group directly led to the NIHR funded TURING trial in FSGS and minimal change that is currently recruiting.
  - iii. Advisor to numerous Pharma companies on the design and analysis of RCTs in GN (incl Achillion, Alexion, GSK, Pfizer, Medimmune, Aurinia and BMS).
  - iv. Contribute to national and international guidelines and reviews of best management in SLE, LN and other GNs as well as NICE STAs of belimumab in lupus, belimumab in LN and anifrolumab in LN
  - v. Trustee of Kidney Research UK and on the Research Strategy Committee.

## **2. Improving outcomes for women with kidney disease who wish to have children**

- a. Development of the multidisciplinary West London obstetric renal service from scratch in 1996 – have followed more than 1000 women through pregnancy and started a dedicated pre pregnancy counselling clinic in 2010. Our experience has informed practice nationally and internationally; have trained / mentored many obstetric renal /physicians and taught nearly all UK Renal SpRs about pregnancy and CKD.*
- b. Established the Renal Association Rare Renal Pregnancy and CKD group where all women with kidney disease who are pregnant can be registered and allows identification of unmet need, up to date outcome data and has generated multiple collaborative projects and funding.*
- c. Co wrote the world’s first Guideline on Pregnancy and Kidney Disease (published by the Renal Association in 2019, NICE accredited). Gold standard for best care of women with kidney disease before, during and after pregnancy*
- d. Have defined the biomarkers that distinguish CKD and preeclampsia, normal kidney function in pregnancy and the impact of CKD on pregnancy outcomes and kidney function – all of which now allows much more personalised risk assesment of women with CKD planning a pregnancy*
- e. Have contributed to clinical trials and observational studies in pregnancy including SAVE-UK (treating preeclampsia by removal of sFLT) and the PREDICT study (current, KRUK funded, incorporating the ORCHARD study of Beetroot juice in pregnant women with CKD).*
- f. Advise on pregnancies in women with CKD nationally and internationally*

## **3. Responding to the COVID pandemic – contributing to standardizing and improving patient outcomes**

- a. Member and since Dec 2020 CoChair of the ICHNT COVID Treatment group – developed continuously updated Trust guideline (by Sept 21<sup>st</sup> 2021 on to v15!); operationalized use of dexamethasone, remdesivir & tocilizumab; provide on call rota (1 pharmacist + 1 physician on 1 in 5 rota with almost continuous oversight by co-chairs) 7d/week, 8am-9pm initially for all use of new drugs but now for those with cautions or queries. Highly valued clinical service. Supported recruitment of patients to COVID clinical trials. See Satta et al 2021 for how we did this. Sept 2021 -operationalising the use of anti SARS-COV-2 MAbs for clinical use in the Trust.*
- b. Co-chaired the Trust COVID Rapid Synthesis of Best Evidence group to produce rapid reviews of key literature in the early days of the pandemic e.g. evidence on infected vs infectious (clearly demonstrated isolation should be for 10 not 7 days well before government advice); use of preop CT to exclude COVID-19 for patients needing emergency surgery.*



- c. *Core member of the Imperial Renal COVID Immune Response group* (along with Drs Willicombe, McAdoo & Thomas) through which we initiated very early REC approved serial sample collection in our highly vulnerable renal patients. The huge output from this group generated data informing JCVI regarding the need for 3<sup>rd</sup> primary doses of COVID vaccine in immunosuppressed patients, & contributed to the OCTAVE and OCTAVE-DUO studies.
  - d. *Initiated the first vaccinations of dialysis patients in the UK* via the OCTAVE study a& sourcing vaccine prior to it being generally available for this group. Drove the agenda to ensure dialysis patients became a national priority for early vaccination. See Gleeson et al 2021
  - e. One of two clinician members of the *Data Safety Monitoring Board of the TACTIC-R platform trial* treating COVID-19
  - f. *Personally vaccinated patients and staff* from the start of the vaccination programme. Have directly addressed vaccine hesitancy in many patients and staff and succeeded in persuading many to be vaccinated.
4. **Training next generation of academic doctors:** prior lead roles in NWT Foundation school; WLondon renal training academic lead til 2020, educational supervisor to many academic trainees; mentor UK & international trainees esp women

## PUBLICATIONS 2019-2022

1. Turner-Stokes T, Edwards H and **Lightstone L** *COVID-19 in patients with glomerular disease* Curr Opin Nephrol Hypertens 2022; 31:191-198
2. Beckwith H, **Lightstone L**, McAdoo S *Sex and gender in glomerular disease* Seminars in Nephrology 2022; 42:185-96
3. PHOSP-COVID Collaborative group *Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalization in the UK: a prospective observational study*. Lancet Respir Med 2022 Apr 22:S2213-2600(22)00127-8. Doi:10.1016/S2213-2600(22)00127-8
4. Spensley KJ, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, Thomas D, McAdoo SP, Randell P, Kelleher P, Bedi R, **Lightstone L**, Predecki M, and Willicombe M *Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in haemodialysis patients* Kidney Int Rep 2022 Apr 13. Doi: 10.1016/j.ekir.2022.014.005 Online ahead of print
5. Willicombe M, Scanlon M, Loud F and **Lightstone L** *Should we be clinically assessing antibody responses to covid vaccines in immunocompromised people?* BMJ 2022; April 12; 377:o966. Doi: 10.1136/bmj.o966
6. Jesudason S, Hewawasam E, Moloney B, Tan R, Li J, Blakey H, Bramham K, Hall M, Juneja R, Jarvis E, **Lightstone L**, Lipkin G and Hladunewich MA *Comparison of catheters or new arteriovenous fistulas for commencement of haemodialysis in pregnant women with chronic kidney disease: an international observational study* J Nephrol 2022; 35:1689-1698
7. Gilmore AC, Wilson HR, Cairns TD, Botto M, **Lightstone L**, Bruce IN, Cook TH, Pickering MC. MASTERPLANS Consortium *Immune gene expression and functional networks in distinct lupus nephritis classes* Lupus Sci Med 2022 9(1):e000615
8. Gleeson S and Lightstone L *BLISS LN trial revisited – function matters* Kidney Int 2022; 101:224-226
9. Greenhalgh T, Griffin S, Gurdasani D, Hamdy A, Katzourakis A, McKee M, Michie S, Pagel C, Roberts R, Yates K, on behalf of full list of signatories. *Covid-19: an urgent call for global “vaccines-plus” action*. BMJ 2022 doi: 10.1136/bmj.o1.
10. Waldman M, Soler MJ, Garcia-Carro C, **Lightstone L**, Turner-Stokes T, Griffith M et al *Covid-19 in patients with glomerular disease: follow-up results from the IROC-GN international registry* Kidney 360 2021; 3:293-306
11. Carter SA, Teng C, Gutman T, Logeman C, Cattran D, **Lightstone L**, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster DJ, Coppo R, Fervenza FC, Floege J, Hladunewich MA, Hogan JJ, Kitching AR, Lafayette RA, Malar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Azukaitis K, Cho Y, Shun SF, Ka-Hang Tong M, Teixeira-Pinto A, Wilkie M, Alexander SI, Craig JC, Martin A, Tong A. *A focus group of study of self-management in patients with glomerular disease*. Kidney Int Rep 2021; 30:56-67.
12. Carter SA, **Lightstone L**, Cattran D, Tong A, Bagga A, Barbour SJ, Boletis J, Caster DJ, Coppo R, Fervenza FC, Floege J, Hladunewich MA, Hogan JJ, Kitching AR, Lafayette RA, Malvar A, Radhakrishnan J, Rovin BH, Scholes-Robertson N, Trimarchi H, Zhang H, Anumudu S, Cho Y, Gutman T, O’Lone E, Vieceilli AK, Au E, Azukaitis K Baumgart A, Bernier-Jean A, Dunn L, Howell M, Ju A, Logeman C, Nataatmadja M, Sautenet B, Sharma A, Craig JC; SONG-GD Workshop Investigators. *A core outcome set for trials in glomerular disease: A report of the standardized outcomes in nephrology-Glomerular Disease (SONG-GD) stakeholder workshops* Clin J Am Soc Nephrol 2022;17:53-64.
13. Shipa M, Embleton-Thirsk A, Parvaz M, Ribeiro Santos L, Muller P, Chowdhury K, Isenberg D, Dore C, Gordon C and Ehrenstein M on behalf of the BEAT-LUPUS Investigators (includes **L Lightstone**) *Effectiveness of belimumab after rituximab in systemic lupus erythematosus A randomized controlled trial* Annals Int Med 2021; 174:1647-1657
14. Majeed A, Hodes S, Loud F, and **Lightstone L** *Setting up a vaccination programme for immunocompromised patients* BMJ Opinion 2021 <https://blogs.bmj.com/bmj/2021/10/19/setting-up-a-vaccination-programme-for-immunocompromised-patients/> Published online 19.10.2021
15. Evans RA, McAuley H, Harrison EM, Shikotra A, Singpuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, Daines L, Baillie JK, Brown JS, Chalder T, de Soyza A, Diar Bakerly N, Eason N, Geddes JR, Greening NJ, Hart N, Heaney G Heller S, Howard L, Hurst JR, Jacob J, Jenkins RG, Jolley C, Kerr S, Kon OM, Lewis K, Lord JM, McCann GP, Neubauer S, Openshaw PJM, Parekh D, Pfeffer P, Rahman NM, Rama B, Richardson M, Rowland M, Semple MF, Shah AM, Singh SJ, Sheikh A, Thomas D, Toshner M, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Wain LV, Brightling CE; PHOSP-COVID Collaborative Group *Physical, cognitive, and mental health impacts of COVID-19 after hospitalization*

- (PHOSP-COVID): a UK Multicentre, prospective cohort study *Lancet Respir Med* 2021 Oct 7:S2213-2600(21)00383-0. Doi: 10.1016/S2213-2600(21)00383-0. Online ahead of print.
16. Predecki M, Thomson T, Clarke CL, Martin P, Gleeson S, Cardoso de Aguiar R, Edwards H, Mortimer P, McIntyre S, Mokri D, Cox A, Pickard G, **Lightstone L**, Thomas D, McAdoo SP, Keller P, Willicombe M, and the Imperial Renal COVID-19 vaccine study group in collaboration with the OCTAVE Study Consortium. *Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients*. *Lancet* 2021 Oct 4:S0140-6736(21)02096-1. doi: 10.1016/S0140-6736(21)02096-1. Online ahead of print
  17. Predecki M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S, Martin P, Thomson T, Randell P, Shah A, Singanayagam A, **Lightstone L**, Cox A, Kelleher P, Willicombe M and McAdoo S *Humoral and T cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression* *Ann Rheum Dis* 2021; 80:1322-1329
  18. Medjeral-Thomas NR, Trolborg A, Hansen AG, Gisby J, Clarke CL, Predecki M, McAdoo SP, Sandhu E, **Lightstone L**, et al. *Plasma lectin pathway complement proteins in patients with COVID-19 and renal disease* *Front Immunol* 2021; Apr 29;12:671052 doi:10.3389/fimmu.2021.671052.
  19. Carter SA, Logeman C, Howell M, Catran D, **Lightstone L**, et al. *Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease* *Kidney Int* 2021 May 5:S0085-2538(21)00468-3 doi:10.1016/j.kint.2021.04.027 Online ahead of print
  20. Buang N, Tapeng L, Gray V, Sardini A, Whilding C, **Lightstone L**, Cairns T, Pickering MC, Behmouras J, Ling GS, and Botto M *Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus* *Nature Commun* 2021; Mar 31;12(1):1980. Doi: 10.1038/s41467-021-22312-y
  21. Gleeson S, Martin P, Bedi R, Lynch K, Willicombe M and **Lightstone L** *Answering the call to action: Rapid implementation of an in-centre haemodialysis SARS-CoV-2 vaccination programme*. *Kidney Int* 2021; 99:1238-1239
  22. Satta G, Youngstein T, **Lightstone L** and Gilchrist M on behalf of the COVID-19 treatment guideline working group at ICHNT. *The utility of a local multidisciplinary treatment team to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic*. *Clin Med (Lond)* 2021;21:e287-e289.1021.
  23. Clarke CL, Predecki M, Dhutia A, Gan J, Edwards C, Prout V, **Lightstone L**, et al. *Longevity of SARS-CoV-2 immune responses in haemodialysis patients and protection against reinfection* *Kidney Int* 2021; 99:1470-1477
  24. Gleeson S, Cardoso F, **Lightstone L**, Webster P, Munro K and Cairns T. *A new approach to de novo minimal change disease in pregnancy* *Nephrology (Carlton)* 2021; 26:692-693. doi: 10.1111/neph.13871 Online ahead of print
  25. Predecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Dalla Pria A, **Lightstone L**, Xu X-N, Barclay W, McAdoo S, Kelleher P, and Willicombe M. *Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single dose BNT162b2 vaccine*. *The Lancet* 2021; 397:1178-1181
  26. Turner-Stokes T, Jiang E, Johnson N, Khakhria K, Kong E, Cairns T, Clarke C, Greathead L, Griffith M, Guckian M, Kelleher P, McClure MO, Predecki M, Rosadas C, Tedder R, **Lightstone L**, Willicombe M, McAdoo SP; ICHNT Renal COVID-19 Group. *Serological screening for COVID-19 in patients with glomerular disease*. *Kidney Int Rep* 2021;6:1402-1406.
  27. Wiles, K et al *Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease*. *Pregnancy Hypertension* 2021; 24:58-64
  28. Willicombe M, Gleeson S, Clarke C, Dor F, Predecki M, **Lightstone L**, Lucisano G, McAdoo S, Thomas D; ICHNT Renal COVID Group. *Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening*. *Transplantation*. 2021;105:151-157
  29. Waldman M, Soler MJ, García-Carro C, **Lightstone L**, Turner-Stokes T, Griffith M, et al. *Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring*. *Kidney Int*. 2021; 99:227-237
  30. Clarke C, Lucisano G, Predecki M, Gleeson S, Martin P, Ali M, McAdoo SP, **Lightstone L**, et al; ICHNT Renal COVID Group. *Informing the risk of kidney transplantation versus remaining on the wait list in the COVID-19 era*. *Kidney Int Rep*. 2021; 6:46-55 Published online ahead of print Nov 2020.PMID: 33173838
  31. Gleeson S and **Lightstone L** *Glomerular disease and pregnancy* *Adv Chronic Kidney Dis* 2020;27:469-76
  32. Predecki M, Clarke C, McKinnon T, **Lightstone L**, Pickering MC, Thomas DC, McAdoo SP and Willicombe M *SARS-CoV-2 antibody point-of-care testing in dialysis and kidney transplant patients with COVID-19* *Kidney Medicine* 2020;3:54-59
  33. Wiles K, Webster P, Seed PT, Bennett-Richards K, Bramham K, Brunskill N, Carr S, Hall M, Khan R, Nelson-Piercy C, Webster LM, Chappell LC & **Lightstone L**. *The Impact of Chronic Kidney Disease Stages 3-5 on Pregnancy Outcomes*. *Nephrol Dial Transplant* 2021; 36: 2008-2017; Featured in an NIHR alert: <https://evidence.nihr.ac.uk/alert/women-kidney-disease-given-risk-assessment-pregnancy/>
  34. Gleeson S, Noori M, **Lightstone L**, Webster P.J *Lesson for the clinical nephrologist: Kidney transplant, COVID-19 and pregnancy*. *J Nephrol*. 2021;34:369-371 epub Nov 2020 PMID: 33180315
  35. Clarke C, Predecki M, Dhutia A, Ali MA, Sajjad H, Shivakumar O, **Lightstone L**, et al *High prevalence of asymptomatic COVID-19 infection in haemodialysis patients detected using serologic screening* *J Am Soc Nephrol* 2020; 31:1969-1975
  36. Tong A, Levey AS, Eckardt KU, Anumudu S, Arce DM, Baumgart A, Dunn L, Gutman T, Harris T, **Lightstone L**, et al *Patient and caregiver perspectives on terms used to describe kidney health* *Clin J Am Soc Nephrol* 2020; 15:937-948

37. Gonzalez A, Gutman T, Lopez-Varga P, Anumudu S, Arce CM, Craig JC, Dunn L, Eckardt K, Harris T, Levey AS, **Lightstone L**, et al. *Patient and caregiver priorities for outcomes in CKD: A multinational nominal group technique study* Am J Kidney Dis 2020; 76:679-689 doi: 10.1053/j.ajkd.2020.03.022.
38. Carter S, Gutman T, Logeman C, Cattran D, **Lightstone L**, et al; SONG-GD Investigators. *Identifying outcomes important to patients with glomerular disease and their caregivers* Clin J Am Soc Nephrol 2020 15:673-684
39. Wiles K, Chappell L, **Lightstone L**, and Bramham K *Updates in diagnosis and management of preeclampsia in women with CKD* Clin J Am Soc Nephrol 2020; 15:1371-1380
40. Wiles K, Anckaert E, Holden F, Grace J, Nelson-Piercy C, **Lightstone L**, Chappell L and Bramham K *Anti-Mullerian hormone concentrations in women with chronic kidney disease* Clinical Kidney J 2019;14:537-542
41. Medjeral-Thomas N, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, Pattison J, Bhandari S, Barrat J, Turner N, Cook HT, Levy J, **Lightstone L**, et al; *Randomised, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicentre, randomised, controlled trial* Clin J Am Soc Nephrol 2020; 15:209-18
42. Wiles K, Chappell L, Clark K, Elman L, Hall M, **Lightstone L**, et al; *Renal Association Clinical Practice Guideline (NICE assured): Pregnancy and Renal Disease 2019* <https://renal.org/wp-content/uploads/2019/09/FINAL-Pregnancy-Guideline-September-2019.pdf> and BMC Nephrol 2019; 20:401-444
43. Nikolopoulou A, Condon M, Turner-Stokes T, Cook HT, Duncan N, Galliford JW, Levy JB, **Lightstone L**, et al. *Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial*. BMC Nephrol. 2019; 20:352
44. Foschi V, Bortolotti D, Doyle AF, Stratigou V, Stephens L, Trivedi P, Rinaldi R, Padovan M, Bortoluzzi A, **Lightstone L**, et al *Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study* Lupus 2019; 28:1091-1100
45. Wiles K, Bramham K, Seed PT, Kurlak LO, Mistry HD, Nelson-Piercy C, **Lightstone L** and Chappell L *Diagnostic indicators of superimposed pre-eclampsia in women with chronic kidney disease* KIReports 2019; 4:842-53
46. Carter SA, **Lightstone L**, Cattran D, Bagga A et al *Standardised outcomes in Nephrology-Glomerular disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease* Kidney Int 2019; 95:1280-83